Cargando…

Incidence, Treatment and Clinical Impact of Iron Deficiency in Chronic Heart Failure: A Longitudinal Analysis

In patients with heart failure (HF), iron deficiency (ID) is a well-recognized therapeutic target; information about its incidence, patterns of iron repletion, and clinical impact is scarce. This single-centre longitudinal cohort study assessed the rates of ID testing and diagnosis in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Miñana, Gema, Lorenzo, Miguel, Ramirez de Arellano, Antonio, Wächter, Sandra, de la Espriella, Rafael, Sastre, Clara, Mollar, Anna, Núñez, Eduardo, Bodí, Vicent, Sanchis, Juan, Bayés-Genís, Antoni, Núñez, Julio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100536/
https://www.ncbi.nlm.nih.gov/pubmed/35566684
http://dx.doi.org/10.3390/jcm11092559
_version_ 1784706869461254144
author Miñana, Gema
Lorenzo, Miguel
Ramirez de Arellano, Antonio
Wächter, Sandra
de la Espriella, Rafael
Sastre, Clara
Mollar, Anna
Núñez, Eduardo
Bodí, Vicent
Sanchis, Juan
Bayés-Genís, Antoni
Núñez, Julio
author_facet Miñana, Gema
Lorenzo, Miguel
Ramirez de Arellano, Antonio
Wächter, Sandra
de la Espriella, Rafael
Sastre, Clara
Mollar, Anna
Núñez, Eduardo
Bodí, Vicent
Sanchis, Juan
Bayés-Genís, Antoni
Núñez, Julio
author_sort Miñana, Gema
collection PubMed
description In patients with heart failure (HF), iron deficiency (ID) is a well-recognized therapeutic target; information about its incidence, patterns of iron repletion, and clinical impact is scarce. This single-centre longitudinal cohort study assessed the rates of ID testing and diagnosis in patients with stable HF, patterns of treatment with intravenous iron, and clinical impact of intravenous iron on HF rehospitalization risk. We included 711 consecutive outpatients (4400 visits) with stable chronic HF from 2014 to 2019 (median [interquartile range] visits per patient: 2 [2–7]. ID was defined as serum ferritin <100 µg/L, or 100–299 µg/L with transferrin saturation (TSAT) < 20%. During a median follow-up of 2.20 (1.11–3.78) years, ferritin and TSAT were measured at 2230 (50.7%) and 2183 visits (49.6%), respectively. ID was found at 846 (37.9%) visits, with ferritin and TSAT available (2230/4400), and intravenous iron was administered at 321/4400 (7.3%) visits; 233 (32.8%) patients received intravenous iron during follow-up. After multivariate analyses, iron repletion at any time during follow-up was associated with a lower risk of recurrent HF hospitalization (hazard ratio [HR] = 0.50, 95% confidence interval [CI] = 0.28–0.88; p = 0.016). Thus, ID was a frequent finding in patients with HF, and its repletion reduced the risk of recurrent HF hospitalizations.
format Online
Article
Text
id pubmed-9100536
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91005362022-05-14 Incidence, Treatment and Clinical Impact of Iron Deficiency in Chronic Heart Failure: A Longitudinal Analysis Miñana, Gema Lorenzo, Miguel Ramirez de Arellano, Antonio Wächter, Sandra de la Espriella, Rafael Sastre, Clara Mollar, Anna Núñez, Eduardo Bodí, Vicent Sanchis, Juan Bayés-Genís, Antoni Núñez, Julio J Clin Med Article In patients with heart failure (HF), iron deficiency (ID) is a well-recognized therapeutic target; information about its incidence, patterns of iron repletion, and clinical impact is scarce. This single-centre longitudinal cohort study assessed the rates of ID testing and diagnosis in patients with stable HF, patterns of treatment with intravenous iron, and clinical impact of intravenous iron on HF rehospitalization risk. We included 711 consecutive outpatients (4400 visits) with stable chronic HF from 2014 to 2019 (median [interquartile range] visits per patient: 2 [2–7]. ID was defined as serum ferritin <100 µg/L, or 100–299 µg/L with transferrin saturation (TSAT) < 20%. During a median follow-up of 2.20 (1.11–3.78) years, ferritin and TSAT were measured at 2230 (50.7%) and 2183 visits (49.6%), respectively. ID was found at 846 (37.9%) visits, with ferritin and TSAT available (2230/4400), and intravenous iron was administered at 321/4400 (7.3%) visits; 233 (32.8%) patients received intravenous iron during follow-up. After multivariate analyses, iron repletion at any time during follow-up was associated with a lower risk of recurrent HF hospitalization (hazard ratio [HR] = 0.50, 95% confidence interval [CI] = 0.28–0.88; p = 0.016). Thus, ID was a frequent finding in patients with HF, and its repletion reduced the risk of recurrent HF hospitalizations. MDPI 2022-05-02 /pmc/articles/PMC9100536/ /pubmed/35566684 http://dx.doi.org/10.3390/jcm11092559 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Miñana, Gema
Lorenzo, Miguel
Ramirez de Arellano, Antonio
Wächter, Sandra
de la Espriella, Rafael
Sastre, Clara
Mollar, Anna
Núñez, Eduardo
Bodí, Vicent
Sanchis, Juan
Bayés-Genís, Antoni
Núñez, Julio
Incidence, Treatment and Clinical Impact of Iron Deficiency in Chronic Heart Failure: A Longitudinal Analysis
title Incidence, Treatment and Clinical Impact of Iron Deficiency in Chronic Heart Failure: A Longitudinal Analysis
title_full Incidence, Treatment and Clinical Impact of Iron Deficiency in Chronic Heart Failure: A Longitudinal Analysis
title_fullStr Incidence, Treatment and Clinical Impact of Iron Deficiency in Chronic Heart Failure: A Longitudinal Analysis
title_full_unstemmed Incidence, Treatment and Clinical Impact of Iron Deficiency in Chronic Heart Failure: A Longitudinal Analysis
title_short Incidence, Treatment and Clinical Impact of Iron Deficiency in Chronic Heart Failure: A Longitudinal Analysis
title_sort incidence, treatment and clinical impact of iron deficiency in chronic heart failure: a longitudinal analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100536/
https://www.ncbi.nlm.nih.gov/pubmed/35566684
http://dx.doi.org/10.3390/jcm11092559
work_keys_str_mv AT minanagema incidencetreatmentandclinicalimpactofirondeficiencyinchronicheartfailurealongitudinalanalysis
AT lorenzomiguel incidencetreatmentandclinicalimpactofirondeficiencyinchronicheartfailurealongitudinalanalysis
AT ramirezdearellanoantonio incidencetreatmentandclinicalimpactofirondeficiencyinchronicheartfailurealongitudinalanalysis
AT wachtersandra incidencetreatmentandclinicalimpactofirondeficiencyinchronicheartfailurealongitudinalanalysis
AT delaespriellarafael incidencetreatmentandclinicalimpactofirondeficiencyinchronicheartfailurealongitudinalanalysis
AT sastreclara incidencetreatmentandclinicalimpactofirondeficiencyinchronicheartfailurealongitudinalanalysis
AT mollaranna incidencetreatmentandclinicalimpactofirondeficiencyinchronicheartfailurealongitudinalanalysis
AT nunezeduardo incidencetreatmentandclinicalimpactofirondeficiencyinchronicheartfailurealongitudinalanalysis
AT bodivicent incidencetreatmentandclinicalimpactofirondeficiencyinchronicheartfailurealongitudinalanalysis
AT sanchisjuan incidencetreatmentandclinicalimpactofirondeficiencyinchronicheartfailurealongitudinalanalysis
AT bayesgenisantoni incidencetreatmentandclinicalimpactofirondeficiencyinchronicheartfailurealongitudinalanalysis
AT nunezjulio incidencetreatmentandclinicalimpactofirondeficiencyinchronicheartfailurealongitudinalanalysis